I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| enterocyte | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| enterocyte | 3 studies | 21% ± 5% |
Insufficient scRNA-seq data for expression of CYP4F2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 9447.38 | 226 / 226 | 93% | 78.64 | 377 / 406 |
| prostate | 89% | 404.91 | 219 / 245 | 39% | 6.51 | 195 / 502 |
| intestine | 52% | 658.13 | 499 / 966 | 64% | 7.44 | 337 / 527 |
| stomach | 48% | 13.61 | 172 / 359 | 62% | 8.69 | 177 / 286 |
| kidney | 90% | 1071.97 | 80 / 89 | 17% | 1.17 | 153 / 901 |
| ureter | 0% | 0 | 0 / 0 | 100% | 2.40 | 1 / 1 |
| bladder | 48% | 38.52 | 10 / 21 | 34% | 4.11 | 172 / 504 |
| skin | 56% | 57.68 | 1019 / 1809 | 2% | 0.09 | 11 / 472 |
| peripheral blood | 40% | 14.13 | 370 / 929 | 0% | 0 | 0 / 0 |
| esophagus | 15% | 8.32 | 212 / 1445 | 21% | 1.57 | 39 / 183 |
| pancreas | 19% | 6.90 | 61 / 328 | 16% | 0.97 | 29 / 178 |
| breast | 25% | 18.42 | 117 / 459 | 3% | 0.31 | 36 / 1118 |
| brain | 25% | 5.79 | 667 / 2642 | 3% | 0.06 | 19 / 705 |
| uterus | 16% | 4.92 | 28 / 170 | 6% | 0.39 | 28 / 459 |
| lung | 3% | 0.57 | 19 / 578 | 11% | 0.68 | 127 / 1155 |
| spleen | 9% | 16.11 | 22 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 7% | 0.14 | 3 / 45 |
| ovary | 1% | 0.22 | 2 / 180 | 3% | 0.05 | 11 / 430 |
| adipose | 2% | 1.58 | 19 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 1% | 0.31 | 13 / 1335 | 0% | 0 | 0 / 0 |
| adrenal gland | 1% | 0.27 | 2 / 258 | 0% | 0 | 0 / 230 |
| thymus | 1% | 0.20 | 5 / 653 | 0% | 0 | 0 / 605 |
| heart | 1% | 0.30 | 5 / 861 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.01 | 1 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0032305 | Biological process | positive regulation of icosanoid secretion |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0003091 | Biological process | renal water homeostasis |
| GO_0032304 | Biological process | negative regulation of icosanoid secretion |
| GO_0006690 | Biological process | icosanoid metabolic process |
| GO_0008217 | Biological process | regulation of blood pressure |
| GO_0055078 | Biological process | sodium ion homeostasis |
| GO_0007596 | Biological process | blood coagulation |
| GO_0010430 | Biological process | fatty acid omega-oxidation |
| GO_0000038 | Biological process | very long-chain fatty acid metabolic process |
| GO_0042360 | Biological process | vitamin E metabolic process |
| GO_0042361 | Biological process | menaquinone catabolic process |
| GO_0036101 | Biological process | leukotriene B4 catabolic process |
| GO_0003095 | Biological process | pressure natriuresis |
| GO_0097267 | Biological process | omega-hydroxylase P450 pathway |
| GO_0019373 | Biological process | epoxygenase P450 pathway |
| GO_0042377 | Biological process | vitamin K catabolic process |
| GO_0006691 | Biological process | leukotriene metabolic process |
| GO_0001676 | Biological process | long-chain fatty acid metabolic process |
| GO_0042376 | Biological process | phylloquinone catabolic process |
| GO_0019369 | Biological process | arachidonic acid metabolic process |
| GO_0016324 | Cellular component | apical plasma membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0018685 | Molecular function | alkane 1-monooxygenase activity |
| GO_0016709 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen |
| GO_0052869 | Molecular function | arachidonic acid omega-hydroxylase activity |
| GO_0070330 | Molecular function | aromatase activity |
| GO_0052871 | Molecular function | alpha-tocopherol omega-hydroxylase activity |
| GO_0050051 | Molecular function | leukotriene-B4 20-monooxygenase activity |
| GO_0097258 | Molecular function | 20-hydroxy-leukotriene B4 omega oxidase activity |
| GO_0004497 | Molecular function | monooxygenase activity |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0020037 | Molecular function | heme binding |
| GO_0102033 | Molecular function | long-chain fatty acid omega-hydroxylase activity |
| GO_0008392 | Molecular function | arachidonic acid epoxygenase activity |
| GO_0097259 | Molecular function | 20-aldehyde-leukotriene B4 20-monooxygenase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CYP4F2 |
| Protein name | Cytochrome P450 Cytochrome P450 family 4 subfamily F member 2 (Cytochrome P450, family 4, subfamily F, polypeptide 2, isoform CRA_a) Cytochrome P450 family 4 subfamily F member 2 Cytochrome P450 4F2 (EC 1.14.14.1) (20-hydroxyeicosatetraenoic acid synthase) (20-HETE synthase) (Arachidonic acid omega-hydroxylase) (CYPIVF2) (Cytochrome P450-LTB-omega) (Docosahexaenoic acid omega-hydroxylase) (EC 1.14.14.79) (Leukotriene-B(4) 20-monooxygenase 1) (Leukotriene-B(4) omega-hydroxylase 1) (EC 1.14.14.94) (Phylloquinone omega-hydroxylase CYP4F2) (EC 1.14.14.78) |
| Synonyms | hCG_1788543 |
| Description | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, eicosanoids and vitamins . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of long- and very long-chain fatty acids. Displays high omega-hydroxylase activity toward polyunsaturated fatty acids (PUFAs) . Participates in the conversion of arachidonic acid to omega-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure . Plays a role in the oxidative inactivation of eicosanoids, including both pro-inflammatory and anti-inflammatory mediators such as leukotriene B4 (LTB4), lipoxin A4 (LXA4), and several HETEs . Catalyzes omega-hydroxylation of 3-hydroxy fatty acids . Converts monoepoxides of linoleic acid leukotoxin and isoleukotoxin to omega-hydroxylated metabolites . Contributes to the degradation of very long-chain fatty acids (VLCFAs) by catalyzing successive omega-oxidations and chain shortening . Plays an important role in vitamin metabolism by chain shortening. Catalyzes omega-hydroxylation of the phytyl chain of tocopherols (forms of vitamin E), with preference for gamma-tocopherols over alpha-tocopherols, thus promoting retention of alpha-tocopherols in tissues . Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation . . |
| Accessions | ENST00000589654.2 ENST00000586927.2 ENST00000221700.11 [P78329-1] K7EK90 ENST00000011989.11 A0A0A0MQR0 ENST00000587671.2 O95743 K7EPM0 P78329 K7EQI8 |
